EYEGENE Inc.
tradeKorea tradeshows company E-catalog
tradeKorea tradeshows company E-catalog
EYEGENE Inc.
CEO : Wonil Yoo
Adress |
b-910, 401 Yangcheon-ro, Gangseo-gu, Seoul, Korea |
|
rosybrown@eyegene.co.kr |
Website |
www.eyegene.co.kr/kor |
Phone No. |
82-10-3729-9863 |
Eyegene took its first step in the development of innovative biopharmaceutical drugs when it was first established in june 2020.Since then, Eyegene has continued to research and develop innovative drugs to overcome the deterioration of the quality of life due to aging. Eyegene has two core technologies. EGT022 os a molecule for the treatment of ischemic diseases based on proteomic research. It is being developed as a treatment for diabetic retinopathy, pressure ulcers, wound healing, and Myocardial ischemia/Reperfusion Injury. Various Premium Vaccines for adults are also being developed using Eyegene's proprietary Adjuvant, which has been established through continuous research in the field of immunology.
EG-R mRNA Delivery System
A liposome is a spherical-shaped vesicle that is composed of phospholipid bilayers, which closely resembles the structure of cell membranes, and exhibited biocompatibility and biodegradability. Liposomes have long been used as drug delivery or adjuvant for human vaccine. Here, we suggested novel cationic liposome-based mRNA delivery systems called EG-R. EG-R are compo ...View more
Trade Price / Negotiable
MOQ / Min. Order
tradeKorea tradeshows company E-catalog